Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:46 PM ET 8-K
Nasdaq/NYSE Compliance Notice Cable One, Inc. CABO

Cable One Nasdaq/NYSE Compliance Notice

Cable One received a deficiency notice from the NYSE because its average global market capitalization and stockholders' equity both fell below the $50 million minimum requirement. The company has 45 days to submit a plan to regain compliance within an 18-month cure period. Additionally, the company disclosed it missed a $10 million interest payment on its 4.00% senior notes due 2030, entering a 30-day grace period.

Counterparty
New York Stock Exchange
Term
18 months
4:46 PM ET 8-K
Capital Raise Zoomcar Holdings, Inc.

Zoomcar Holdings Capital Raise

Zoomcar Holdings completed the eighth closing of its private placement, issuing 100 Series A units for gross proceeds of $100,000. Each unit consists of one share of Series A Convertible Preferred Stock and a warrant to purchase 20,000 shares of common stock. The company has extended the termination date of the overall $5 million offering (plus a $5 million overallotment option) to November 30, 2026.

4:42 PM ET 8-K
Nasdaq/NYSE Compliance Notice XMax Inc. XMAX

XMax Nasdaq/NYSE Compliance Notice

XMAX Inc. received a Letter of Reprimand from Nasdaq for failing to obtain shareholder approval prior to issuing more than 20% of its common stock at a discount to the minimum price. Nasdaq determined that delisting was not an appropriate sanction because shareholders subsequently ratified the issuances at a special meeting on November 2, 2026. The matter is now closed and the company's common stock continues to trade on the Nasdaq Stock Market.

Counterparty
Nasdaq
4:41 PM ET 8-K
Capacity Expansion Mdu Resources Group Inc MDU

Mdu Resources Group Capacity Expansion: $3.49B Investment

MDU Resources announced a $3.5 billion five-year capital investment plan for 2027-2031, a 12% increase over its previous plan. The company also highlighted an additional $2.8 billion to $3.1 billion investment for the Bakken East pipeline project, which it intends to lead while evaluating potential financial or strategic partners.

Value
$3.49B
Term
2027-2031
4:41 PM ET 8-K
Nasdaq/NYSE Compliance Notice Lakewood-Amedex Biotherapeutics Inc. LABT

Lakewood-Amedex Biotherapeutics Nasdaq/NYSE Compliance Notice

Lakewood-Amedex Biotherapeutics received a delisting notice from Nasdaq on November 10, 2026, because its common stock failed to maintain the $1.00 minimum bid price for 30 consecutive business days. Due to a prior reverse stock split within the last year, the company is ineligible for a standard compliance period and faces immediate suspension unless it successfully appeals to a Nasdaq Hearings Panel. The company intends to request a hearing to stay the delisting and present a plan to regain compliance.

Counterparty
The Nasdaq Stock Market LLC
4:39 PM ET 8-K
M&A Deal Installed Building Products, Inc. IBP

Installed Building Products M&A Deal with Take Pride Insulation, LLC

Installed Building Products, Inc. (IBP) has acquired Take Pride Insulation, LLC, a Montana-based installer of spray foam, fiberglass, and rockwool insulation. The acquisition adds over $6 million in annual revenue and expands IBP's footprint in the Mountain West region. This deal brings IBP's total acquired annual revenue for 2026 to approximately $444 million.

Counterparty
Take Pride Insulation, LLC
4:37 PM ET 8-K
M&A Deal Aethlon Medical Inc AEMD

Aethlon Medical M&A Deal with North Immunology, Inc.

Aethlon Medical provided a status update on its pending merger with North Immunology, Inc., originally announced on September 17, 2026. The filing includes an updated investor presentation that North Immunology will use in meetings with investors regarding the transaction and a concurrent private placement.

Counterparty
North Immunology, Inc.
4:37 PM ET 8-K
Capital Raise Vivani Medical, Inc. VANI

Vivani Medical Capital Raise of $5.1M

Vivani Medical entered into a share purchase agreement for a $5.1 million private placement of common stock with board members Gregg Williams and Aaron Mendelsohn. The shares were priced at $1.01 per share, representing an at-the-market transaction based on the prior trading day's close. Proceeds will be used to fund the clinical development of NPM-139, the company's semaglutide implant for weight maintenance.

Value
$5.1M
Counterparty
Gregg Williams and Aaron Mendelsohn
4:37 PM ET 8-K
M&A Deal Standard Biotools Inc. LAB

Standard Biotools M&A Deal with Treeline Biosciences, Inc.

Standard BioTools Inc. provided a status update regarding its pending acquisition of Treeline Biosciences, Inc., specifically addressing stockholder litigation and demand letters. To avoid potential business delays and moot disclosure claims, the company issued supplemental disclosures to its definitive proxy statement ahead of the special meeting of stockholders scheduled for November 19, 2026.

Counterparty
Treeline Biosciences, Inc.
4:32 PM ET 8-K
M&A Deal Diamondback Energy, Inc. FANG

Diamondback Energy M&A Deal with Double Eagle IV Midco, LLC and Double Eagle V Midco, LLC

Diamondback Energy entered into a definitive agreement to acquire certain subsidiaries of Double Eagle for approximately $2.15 billion in cash and 15.56 million shares of common stock. The deal 'nets up' Diamondback's interest in a Midland Basin partnership it already co-owned, adding 176,000 net acres and significant undeveloped inventory. The acquisition is expected to close on December 21, 2026.

Counterparty
Double Eagle IV Midco, LLC and Double Eagle V Midco, LLC
4:30 PM ET 8-K
Capital Raise Keurig Dr Pepper Inc. KDP

Keurig Dr Pepper Capital Raise of $2.3B

Keurig Dr Pepper completed a public offering of 66,666,667 shares of common stock (including the full exercise of the underwriters' option) at a price of $34.50 per share. The company received approximately $2.25 billion in net proceeds, which it intends to use to repay outstanding debt and accelerate deleveraging. This financial move is intended to optimize the balance sheet ahead of the company's planned separation into two independent public companies in early 2027.

Value
$2.3B
Counterparty
Goldman Sachs & Co. LLC
4:29 PM ET 8-K
M&A Deal Pool Corp POOL

Pool M&A Deal with Team Horner Group, Inc.

Pool Corporation (POOL) has signed a definitive agreement to acquire Team Horner Group, Inc., a Florida-based wholesale distributor of swimming pool products. The acquisition includes 18 sales centers and manufacturing operations for pool heat pumps and salt chlorine generators. The deal is expected to close in Q1 2027 and will be funded through POOL's revolving credit facility and cash on hand.

Counterparty
Team Horner Group, Inc.
4:29 PM ET 8-K
Nasdaq/NYSE Compliance Notice Connect Biopharma Holdings Ltd CNTB

Connect Biopharma Holdings Nasdaq/NYSE Compliance Notice

Connect Biopharma received a deficiency notice from Nasdaq on November 12, 2026, because its ordinary shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until May 11, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's shares, which continue to trade under the symbol 'CNTB'.

Counterparty
Nasdaq
Term
180 days

“We believe topline results from our Phase 2 Seabreeze STAT asthma and COPD studies mark a significant inflection point in the development of rademikibart as an add-on treatment to rescue bronchodilators and systemic corticosteroids for the treatment of acute exacerbations.”

Barry Quart, Pharm.D., CEO and Director of Connect Biopharma

“We believe these findings support the potential of rademikibart to redefine how acute exacerbations are managed, addressing both the acute event and the 4-week high-risk period following an exacerbation, to improve patient outcomes and reduce the substantial economic burden on healthcare systems.”

Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
4:29 PM ET 8-K
Clinical Trial Data CervoMed Inc. CRVO

CervoMed Clinical Trial Data

CervoMed presented 24-week interim biomarker data from its Phase 2a trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA). The data showed an exposure-dependent reduction in neurofilament light chain (NfL), a key biomarker of neuronal damage, in patients with higher plasma drug levels. Full 24-week biomarker and clinical data from the study are expected in the first quarter of 2027.

Term
24 weeks
4:28 PM ET 8-K
M&A Deal Rapid Micro Biosystems, Inc. RPID

Rapid Micro Biosystems M&A Deal with Merck KGaA, Darmstadt, Germany

Rapid Micro Biosystems has entered into a definitive merger agreement to be acquired by Merck KGaA, Darmstadt, Germany for $0.75 per share in an all-cash tender offer. Following the transaction, which is expected to close in December 2026, Rapid Micro Biosystems will become a wholly owned subsidiary of Merck KGaA's Life Science business. The deal aims to expand the reach of the Growth Direct platform for automated microbial quality control in pharmaceutical manufacturing.

Counterparty
Merck KGaA, Darmstadt, Germany
4:28 PM ET 8-K/A
Clinical Trial Data Cumberland Pharmaceuticals Inc CPIX

Cumberland Pharmaceuticals Clinical Trial Data

Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis (SSc). The study met its primary objective of demonstrating that ifetroban was generally well tolerated with a safety profile consistent with prior experience, though the trial was not powered to detect significant efficacy differences due to limited disease progression in both groups.

Term
12 months
4:28 PM ET 8-K
M&A Deal Aytu Biopharma, Inc AYTU

Aytu Biopharma Signs $56M M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.

Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share in cash, representing a total deal value of approximately $56 million. The transaction will be structured as a cash tender offer followed by a merger and is expected to close by the end of calendar 2026. The company also reported Q1 fiscal 2027 revenue of $14.8 million alongside the merger announcement.

Value
$56M
Counterparty
Rosemont Pharmaceuticals Holdings, Inc.

“Today, we announced that Aytu has entered into a definitive agreement to be acquired by Rosemont for $2.70 per share in cash. This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve.”

Josh Disbrow, Chief Executive Officer of Aytu

“Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”

Josh Disbrow, Chief Executive Officer of Aytu
4:09 PM ET 8-K
M&A Deal Hancock Whitney Corp HWC

Hancock Whitney M&A Deal with Trustmark Corporation

Hancock Whitney Corporation has entered into a definitive agreement to acquire Trustmark Corporation in an all-stock merger. Trustmark shareholders will receive 0.7463 shares of Hancock Whitney common stock for each share of Trustmark they own. Following the merger, Trustmark Bank will be merged into Hancock Whitney Bank, and five Trustmark directors will join the Hancock Whitney board.

Counterparty
Trustmark Corporation
4:09 PM ET 8-K
Clinical Trial Data Mira Pharmaceuticals, Inc. MIRA

Mira Pharmaceuticals Clinical Trial Data

MIRA Pharmaceuticals announced new pharmacological findings for its investigational oral drug candidate MIRA-55, demonstrating high receptor selectivity for CB2 over opioid and COX receptors. The expanded screening showed a 500-fold separation from opioid receptor interactions, supporting its development as a differentiated non-opioid treatment for inflammatory pain. The company is currently advancing IND-enabling activities with a target submission date in the first half of 2027.

4:09 PM ET 8-K
M&A Deal Aytu Biopharma, Inc AYTU

Aytu Biopharma M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.

Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals for $2.70 per share in an all-cash tender offer. The deal represents a 51.7% premium to Aytu's closing price on November 13, 2026, and is expected to close by the end of 2026. Upon completion, Aytu will become a wholly owned subsidiary of Rosemont, supporting Rosemont's U.S. growth strategy in the CNS and pediatric specialty pharmaceutical markets.

Counterparty
Rosemont Pharmaceuticals Holdings, Inc.
3:44 PM ET 8-K
Product Launch Bioxytran, Inc BIXT

Bioxytran Product Launch

Bioxytran, Inc. announced the commercial launch of its first two nutraceutical products, A-SUQAR for metabolic support and V-LO for immune support. The launch marks the clinical-stage biotech's expansion into the consumer wellness market, utilizing its carbohydrate-chemistry expertise. Both products are available immediately through the company's online storefront.

“For years, our team has worked on complex therapeutics for critical care and infectious diseases. Today we are bringing that same science directly to people’s doorsteps. Our entry into nutraceuticals is driven by a simple principle: apply rigorous scientific standards to everyday health. We have held these products to the same diligence we apply to our drug programs, so consumers get a high-quality, science-backed supplement they can trust.”

David Platt, Ph.D., Chief Executive Officer of Bioxytran
3:26 PM ET 8-K
Divestiture Bluerock Homes Trust, Inc. BHM

Bluerock Homes Trust Divestiture for $6.5M

Bluerock Homes Trust completed the disposition of 20 single-family residential units within its Ballast portfolio between August 12 and November 9, 2026. The units were sold to unaffiliated third parties for an aggregate sales price of approximately $6.5 million, resulting in net proceeds of $5.8 million. This transaction is part of a larger divestiture program involving 65 units from the portfolio throughout 2026.

Value
$6.5M
11:49 AM ET 8-K/A
M&A Deal Datz World Holdings Corp. BOTX

Datz World Holdings M&A Deal with RagingBull.com, LLC

DATZ World Holdings Corp. filed an amendment to its 8-K to provide required audited financial statements and pro forma financial information following its acquisition of RagingBull.com, LLC. The acquisition was previously completed on June 8, 2026, and this filing serves as a mandatory regulatory update to include the target company's historical financial performance.

Counterparty
RagingBull.com, LLC
10:18 AM ET 8-K
M&A Deal Rapid Micro Biosystems, Inc. RPID

Rapid Micro Biosystems M&A Deal with Merck KGaA, Darmstadt, Germany

Rapid Micro Biosystems has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The acquisition will be conducted via a tender offer and aims to accelerate the global adoption of Rapid's Growth Direct platform within Merck's Life Science business.

Counterparty
Merck KGaA, Darmstadt, Germany

“We are pleased to report 22% third quarter total revenue growth driven by both our Product and Service businesses. I am also particularly pleased with the continued progress in our gross margin expansion initiatives, which resulted in a third quarter total gross margin of 25%, including record Product and Service gross margins.”

Rob Spignesi, President and CEO

“I'm incredibly proud of what the Rapid Micro team has accomplished and the impact the Growth Direct platform is having across pharmaceutical manufacturing globally. Over the past 18 months, we have built a strong partnership with Merck KGaA, Darmstadt, Germany centered on a shared commitment to innovation and helping customers modernize quality control workflows. We are confident that joining the Life Science business of Merck KGaA, Darmstadt, Germany will significantly expand the Growth Direct's reach, accelerate adoption of the Growth Direct platform and more fully serve our combined global customer base.”

Rob Spignesi, President and CEO
9:42 AM ET 8-K
M&A Deal Cion Investment Corp CION

Cion Investment M&A Deal with BC Partners Advisors L.P.

BC Partners Credit has signed a definitive agreement to acquire a majority controlling interest in CION Investment Management (CIM), the external investment adviser to CION Investment Corporation. CIM will continue to operate independently with its current leadership and investment teams remaining in place, while gaining access to BC Partners' $10 billion private credit platform and origination capabilities. The transaction is expected to close in the first half of 2027, subject to customary conditions and shareholder approval of a new investment advisory agreement.

Counterparty
BC Partners Advisors L.P.
9:30 AM ET 8-K
Capital Raise MapLight Therapeutics, Inc. MPLT

MapLight Therapeutics Capital Raise

MapLight Therapeutics entered into a sales agreement with Leerink Partners to establish an at-the-market (ATM) offering program. The company may sell up to $100 million of its common stock from time to time, with Leerink acting as the sales agent for a commission of up to 3.0%.

Counterparty
Leerink Partners LLC
9:26 AM ET 8-K
Capital Raise Cyabra, Inc. CYAB

Cyabra Capital Raise of $15.6M

Cyabra entered into a securities purchase agreement for a private placement of Series D Preferred Stock and warrants, consisting of an initial $15.6 million closing ($10 million in new cash and $5.6 million via debt cancellation). The agreement also contemplates additional tranches of up to $30 million over three years and the potential establishment of a $50 million equity line of credit.

Value
$15.6M
Counterparty
institutional investors
Term
3 years
9:23 AM ET 8-K
M&A Deal Air Industries Group AIRI

Air Industries Group M&A Deal with Tenax Aerospace Acquisition, LLC

Air Industries Group (AIRI) issued a reminder for a special meeting of stockholders on November 18, 2026, to vote on its proposed merger with Tenax Aerospace Acquisition. Upon closing, Tenax members will own approximately 96% of the combined company, and Tenax will fund the repayment of approximately $26.1 million of AIRI's debt.

Counterparty
Tenax Aerospace Acquisition, LLC
9:19 AM ET 8-K
Regulatory Approval MiniMed Group, Inc. MMED

MiniMed Group Regulatory Approval

MiniMed Group received FDA clearance for its MiniMed Fit™ patch pump, the company's first tubeless insulin pump, several months ahead of schedule. The approval triggers a $162 million one-time R&D payment obligation and has led the company to accelerate its U.S. commercial launch to Spring 2027.

9:13 AM ET 8-K/A
M&A Deal Advanced Micro Devices Inc AMD

Advanced Micro Devices Signs $8.2B M&A Deal with World Labs Technologies, Inc.

Advanced Micro Devices (AMD) completed its acquisition of World Labs Technologies, Inc. on November 13, 2026, for a total purchase price of approximately $8.2 billion. The consideration was paid through the issuance of 14,978,322 shares of AMD common stock to former World Labs stockholders.

Value
$8.2B
Counterparty
World Labs Technologies, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.